Investing.com -- Novo Nordisk (NYSE: NVO ), the Danish pharmaceutical company, announced on Thursday the departure of Camilla Sylvest, the company’s head of commercial strategy and corporate affairs.

The company has quickly moved to fill the vacant position, assigning the responsibilities to Ludovic Helfgott, the current head of Novo’s rare disease unit.

Helfgott will take over Sylvest’s duties immediately, overseeing product and portfolio strategy.

His new remit includes commercial strategy, medical affairs, and business development across all therapy areas, according to the statement released by Novo Nordisk.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.